NCT02373072 - A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

March 31, 2016

Conditions

Idiopathic Parkinson Disease

Interventions

DRUG

PF-06649751

Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.

DRUG

Trimethobenzamide Hydrochloride

300mg TID, Capsules. Optional in both Cohorts.

DRUG

Placebo

Subjects completing all three treatment periods will be receiving placebo once.

Trial Locations (8)

21075

Parkinson's Movement Disorder Center of Maryland, Elkridge

21201

SNBL Clinical Pharmacology Center, Inc., Baltimore

30331

Atlanta Center for Medical Research, Atlanta

33009

MD Clinical, Hallandale

75231

Neurology Consultants of Dallas, PA, Dallas

Walnut Hill Medical Center, Dallas

90806

Collaborative Neuroscience Network, LLC., Long Beach

B-1070

Pfizer Clinical Research Unit, Brussels